Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
25.13B
Market cap25.13B
Price-Earnings ratio
15.86
Price-Earnings ratio15.86
Dividend yield
—
Dividend yield—
Average volume
1.66M
Average volume1.66M
High today
$125.99
High today$125.99
Low today
$123.08
Low today$123.08
Open price
$125.72
Open price$125.72
Volume
1.18M
Volume1.18M
52 Week high
$132.60
52 Week high$132.60
52 Week low
$81.78
52 Week low$81.78

Stock Snapshot

The current Incyte(INCY) stock price is $123.89, with a market capitalization of 25.13B. The stock trades at a price-to-earnings (P/E) ratio of 15.86.

On 2026-09-26, Incyte(INCY) stock traded between a low of $123.08 and a high of $125.99. Shares are currently priced at $123.89, which is +0.7% above the low and -1.7% below the high.

The Incyte(INCY)'s current trading volume is 1.18M, compared to an average daily volume of 1.66M.

During the past year, Incyte(INCY) stock moved between $81.78 at its lowest and $132.60 at its peak.

During the past year, Incyte(INCY) stock moved between $81.78 at its lowest and $132.60 at its peak.

INCY News

TipRanks 14h
Mirum Pharmaceuticals, Incyte announce FDA approval of Atebrioz

Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced that the U.S. FDA has approved Atebrioz tablets to reduce the volume of total new heterotopic ossificat...

Simply Wall St 2d
Incyte Stock Could Be 33% Overvalued After Fresh EADV Data

has delivered a powerful share price run over the past few years, which naturally puts the spotlight on whether that climb is backed by the cash the business ca...

Incyte Stock Could Be 33% Overvalued After Fresh EADV Data
Barron's 3d
Argenx, Arrowhead, Incyte, and Other ‘Moonshot’ Biotech Stocks to Watch - Barron's

...

Argenx, Arrowhead, Incyte, and Other ‘Moonshot’ Biotech Stocks to Watch - Barron's

Analyst ratings

52%

of 31 ratings
Buy
41.9%
Hold
51.6%
Sell
6.5%

More INCY News

Nasdaq 6d
Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target

Incyte (NASDAQ:INCY) executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the...

Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target
Simply Wall St 7d
Does Earlier MINJUVI Access Change The Bull Case For Incyte?

Incyte reported that MINJUVI, a humanized anti CD19 antibody used with rituximab and lenalidomide for relapsed or refractory follicular lymphoma, is now funded...

Does Earlier MINJUVI Access Change The Bull Case For Incyte?

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.